Skip to main content

Mikhail Gishizky New CSO of Entelos; Patricia Randall New General Counsel of Matritech; Cheri Walker, Mark Gardner New VPs at Invitrogen; and Others

NEW YORK, Dec. 17 (GenomeWeb News) -Mikhail Gishizky has been named chief scientific officer of Entelos, the company said today.

 

Gishizky joins Entelos, which markets PhysioLab systems biology technology, from Sugen/Pharmacia, where he was vice president of target discovery. At Sugen/Pharmacia, he established the human cancer genetics program.


 

Patricia Randall has been appointed vice president, general counsel, and chief legal officer of Matritech, the proteomics company said Dec. 16.

 

Randall was most recently vice president and general counsel at Robotic Vision Systems, a machine vision technology company. From 1998 to 2000, she was vice president and general counsel at Hadco, a manufacturer of electronic products. Prior to that, she was a partner at Hamilton, Dahmen & Randall and an adjunct professor at Northeastern University School of Law.


 

Cheri Walker has been appointed vice president, corporate development and Mark Gardner has been appointed vice president of process improvement at Invitrogen, the company said Dec. 15.

 

Walker comes to Invitrogen, of Carlsbad, Calif., from Deutsche Bank, where she was vice president, North American Equity research.

 

Gardner is a Six Sigma Master Black Belt--which means that he has completed a special program on best practices in management. His prior experience includes six sigma and acquisition integration at the IT division of General Electric Medical Systems. Before joining GE, he was a consultant at McKinsey & Company and a lieutenant commander and pilot in the United States Navy.


 

Charles Cantor has been appointed to the scientific advisory voard of GeneGo, the St. Joseph, Mich., company said Dec. 15.

 

Cantor is currently the chief scientific officer of Sequenom, and the director of the center for advanced biotechnology at Boston University. He has also held academic positions at Columbia University and University of California at Berkeley, and was director of the Department of Energy Human Genome Center at Lawrence Berkeley National Laboratory. In 2002, he founded SelectX Pharmaceuticals.


 

Bertrand Jordan, Daniel Chan, Herb Heyneker, and Peter Lockey have all been appointed to the scientific advisory board of PamGene, the company said Dec. 15

 

The Den Bosch, Netherlands microarray company said its board now includes eight members in areas such as oncology, infectious diseases, bioinformatics, genetics, pharmaceutical research and development, immunology and proteomics.

 

Jordan is a molecular biologist whose work focuses on large-scale transcript analyis and genomics research, and has been a director of research at France's Centre Nationale de Recherches Scientifiques, or CNRS.

 

Chan is a professor of Pathology, Oncology, Urology and Radiology at the John Hopkins University Medical School,and Director of Clinical Chemistry, Johns Hopkins Hospital, as well as the director of the biomarker discovery center at Hopkins' Sidney Kimmel Comprehensive Cancer Center. His research focuses on cancer proteomics using techniques such as SELDI-TOF mass spectrometry, according to the cancer center's web site.

 

Heyneker is a veteran in biotechnology R&D. After having served as the founding chief scientific officer of Genentech from 1976 to 1984, he joined the spinoff Genencor as vice president of R&D. He also founded Eos, a biotechnology company, and served as chief technology officer until the company was acquired by Protein Design Labs earlier this year. He now as an advisor to Abingworth, a Palo Alto- and London- based venture capital firm.

 

Lockey is director of biochemistry and high-throughput screening at Argenta Discovery of Harlow, Essex, UK. Prior to joining Argenta, he led teams in the high throughput screening and assay development groups at Aventis UK.


 

Peter Wagner, senior vice president and CTO of Zyomyx as well as the company founder, has been named one of the ten technology pioneers for 2004 by the World Economic Forum.

 

Wagner has been selected for leadership and "innovative research" in the protein biochip technology field. This technology pioneers program was established in 2000 to identify and integrate companies involved in designing and developing new technologies, to monitor and highlight the innovations, and to explore "possible societal repercussions," according to the WEF.

 

"I am honored to have been selected by the World Economic Forum, and I look forward to contributing to the Technology Pioneers community as a member of this distinguished group," stated Wagner. "I am very proud of the accomplishments Zyomyx has made to the fields of proteomics and bionanotechnology, including this year's launch of the first automated protein profiling biochip system."


 

Krishna Sudhir has been named vice president of medical affairs at Diadexus,  the company said Dec. 12. He joins Diadexus from Millennium Pharmaceuticals, where he was director of clinical research. Previously, he was director of cardiovascular research for Pharmacyclics.

 

Sudhir has been a consulting associate professor of medicine in the cardiology division at Stanford University since 2001. He was an associate professor of medicine at Monash University, consultant cardiologist at the Alfred Hospital, and co-director of the hormones and vasculature research laboratory at the Baker Heart Research Institute in Melbourne, Australia, from 1998-2001.


 

Kenneth Weisshar has been elected to the board of directors of Digene, the Gaithersburg, Md. Company said Dec.11.

 

Weisshaar served as Chief Operating Officer and strategy advisor of Sensatex/Life Link from 2000 to 2003. Before joining Sensatex, he held a number of senior positions at Becton, Dickinson & Company, including chief financial Officer; president, worldwide consumer health care; sector president, bioscience cell analysis; president bd division; and vice president corporate planning and development. From 1982 to 1988 he was a consultant at McKinsey & Company, and was employed by Raychem Corporation from between 1974 and 1982.

 

Digene develops and markets DNA and RNA testing systems for disease screening and diagnosis.

The Scan

US Supports Patent Waivers

NPR reports that the Biden Administration has announced its support for waiving intellectual property protections for SARS-CoV-2 vaccines.

Vaccines Versus Variants

Two studies find the Pfizer-BioNTech SARS-CoV-2 vaccine to be effective against viral variants, and Moderna reports on booster shots to combat variants.

CRISPR for What Ails You

The Wall Street Journal writes that CRISPR-based therapies could someday be used to treat common conditions like heart attacks.

Nature Papers Review Integration of Single-Cell Assay Data, Present Approach to Detect Rare Variants

In Nature this week: review of ways to integrate data from single-cell assays, and more.